Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144168 | 0.93 | HSD17B10 (0.45) | HSD17B10ALDH1A1HTTSLC6A9S1PR1 | |
| SCHEMBL2291856 | 0.80 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL8719367 | 0.80 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL21320722 | 0.78 | HSD17B10 (0.54) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL3862747 | 0.78 | GAA (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL165228 | 0.78 | — | — | |
| SCHEMBL29259191 | 0.77 | HSD17B10 (0.39) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL336249 | 0.76 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL21454626 | 0.76 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL454245 | 0.76 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259306-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2024-12-19 | — | — | WO | disclosed |
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | Bracco Suisse (CH) | 2024-02-20 | — | — | US | disclosed |
| WO-2023245100-A1 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | BRACCO SUISSE SA (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | BRACCO SUISSE SA (CH) | 2022-06-28 | — | — | US | disclosed |
| EP-2125857-A1 | DIAGNOSTIC AND RADIOTHERAPEUTIC CONTRAST AGENTS AND PROCESS FOR THEIR PREPARATION | Bracco Imaging S.p.A (IT) | 2009-12-02 | — | — | EP | disclosed |
| EP-2111237-A2 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING S.p.A. (IT) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008104486-A1 | DIAGNOSTIC AND RADIOTHERAPEUTIC CONTRAST AGENTS AND PROCESS FOR THEIR PREPARATION | BRACCO IMAGING SPA (IT) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008073458-A2 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING S.P.A. (IT) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | HSD17B10 4075/4885GAA 3907/4885ALDH1A1 2114/4885 |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | SELPLG, SELL, SELE | HSD17B10 4075/4885GAA 3907/4885ALDH1A1 2114/4885 |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | HSD17B10 4075/4885GAA 3907/4885ALDH1A1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.